Related Experiment Video

Updated: Aug 29, 2026

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

Preventing renal dysfunction in patients with hypertension: clinical implications from the early AASK Trial results

Janice P Lea1, Denyse T Brown, Michael Lipkowitz

  • 1Emory University School of Medicine, Atlanta, GA, USA. jlea@emory.edu

American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions
|January 20, 2004
PubMed

Insights

Angiotensin-converting enzyme (ACE) inhibitor-based therapy shows a renoprotective effect in patients with hypertension-related kidney disease, potentially due to its antiproteinuric impact independent of blood pressure reduction.

Area of Science:

  • Nephrology
  • Cardiology
  • Hypertension Management

Background:

  • Strategies to slow chronic kidney disease progression often focus on antihypertensive therapy and blood pressure control.
  • Previous studies suggest Angiotensin-Converting Enzyme (ACE) inhibitors offer protection in diabetic kidney disease compared to other antihypertensives.

Purpose of the Study:

  • To review clinical trials on hypertension and kidney disease.
  • To present interim findings from the African-American Study of Kidney Diseases and Hypertension (AASK) on renoprotective effects.

Main Methods:

  • Review of recent clinical trials in hypertension-related kidney disease.
  • Analysis of interim data from the AASK study, a prospective study of African-American patients with hypertensive kidney disease.

Main Results:

  • The AASK study indicates a renoprotective benefit of ACE inhibitor-based therapy over calcium-channel blocker-based therapy.
  • This protective effect may be partly attributed to the antiproteinuric action of ACE inhibitors, irrespective of their blood pressure-lowering effects.

Conclusions:

  • ACE inhibitor-based regimens demonstrate renoprotective properties in hypertensive kidney disease.
  • Antihypertensive strategies incorporating ACE inhibitors may offer superior kidney protection, particularly through antiproteinuric mechanisms.

Related Concept Videos

Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Acute Kidney Injury IV: Diagnostic Studies and Prevention01:30

Acute Kidney Injury IV: Diagnostic Studies and Prevention

Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Antihypertensive Drugs: Potassium-Sparing Diuretics01:28

Antihypertensive Drugs: Potassium-Sparing Diuretics

Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
Factors Affecting Renal Clearance: Renal Impairment01:17

Factors Affecting Renal Clearance: Renal Impairment

Renal dysfunction significantly impairs the renal clearance of drugs, leading to potential complications in drug therapy. Renal failure, which can be caused by various factors, poses a significant challenge in the elimination of drugs from the body.
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...